Vaccinex, Inc.
VCNX · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.03 | 0.03 |
| FCF Yield | -787.96% | -403.84% | -70.59% | -84.89% |
| EV / EBITDA | -0.05 | -0.15 | -1.08 | -1.01 |
| Quality | ||||
| ROIC | 760.66% | 1,108.77% | -350.58% | -288.26% |
| Gross Margin | 100.00% | 100.00% | 68.00% | 81.22% |
| Cash Conversion Ratio | 0.87 | 0.85 | 0.96 | 1.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 81.81% | -14.12% | 25.99% | 19.83% |
| Free Cash Flow Growth | 6.32% | 9.76% | 24.31% | 12.47% |
| Safety | ||||
| Net Debt / EBITDA | 0.06 | 0.07 | 0.30 | 0.38 |
| Interest Coverage | -9,367.50 | -22,885.00 | -9,953.00 | -27.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 508.94 | 615.38 | -2,037.92 | -2,291.51 |